Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 16, 2023 10:01am

119 Views

Post# 35450097

RE:RE:RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

Pre-clinical CD47 company Trillium Therapeutics was acquired by Pfizer for US2.3 Billion late last year without a 'business deal" being telegraphed beforehand. Comparatively, ONCY is a Phase 3 ready cancer company that has "de-risked" their immune molecule platform pelareorep asset in mulitple cancers including breast and pancreatic cancer, as examples.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?